• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Vaccinex Inc (NQ: VCNX )

    2.950 +0.160 (+5.73%)
    Streaming Delayed Price Updated: 3:59 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Vaccinex Inc

    < Previous 1 2 3 4 5 6 Next >
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid, Spain
    Company describes new biomarker and cognitive treatment effects that support continued development of pepinemab in Mild Cognitive Impairment and Mild Dementia due to Alzheimer’s disease 
    From Vaccinex, Inc.
    Via GlobeNewswire
    Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference on October 31, 2024
    In addition to cognitive benefit, pepinemab is believed to preserve vascular integrity in brain, a key consideration to avoid toxicity in Alzheimer’s disease 
    From Vaccinex, Inc.
    Via GlobeNewswire
    VCNX Stock Earnings: Vaccinex Reported Results for Q2 2024
    Vaccinex just reported results for the second quarter of 2024. 
    Via InvestorPlace
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    What's Going On With Vaccinex Stock Wednesday?
    Vaccinex shares are trading lower on Wednesday after the company announced $6.2 million in proceeds from the exercise of warrants as well as the issuance of new warrants for common stock. 
    Via Benzinga
    Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds
    From Vaccinex, Inc.
    Via GlobeNewswire
    VCNX Stock Earnings: Vaccinex Reported Results for Q1 2024
    Vaccinex just reported results for the first quarter of 2024. 
    Via InvestorPlace
    VCNX Stock Earnings: Vaccinex Reported Results for Q4 2023
    Vaccinex just reported results for the fourth quarter of 2023. 
    Via InvestorPlace
    Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development Partnership
    Company reviews goals and significance of the study and outlines development strategy in Mild Cognitive Impairment due to Alzheimer’s disease 
    From Vaccinex, Inc.
    Via GlobeNewswire
    Around $3M Bet On This Energy Stock? Check Out These 3 Stocks Insiders Are Buying
    Via Benzinga
    Why DoorDash Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
    It's time to start off the final trading day of the week with a breakdown of the biggest pre-market stock movers for Friday morning! 
    Via InvestorPlace
    Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease
    From Vaccinex, Inc.
    Via GlobeNewswire
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
    Pre-market stock movers are worth diving into as we check out all of the hottest news affecting shares on Monday morning! 
    Via InvestorPlace
    Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease at the Alzheimer’s Association International Conference, Philadelphia, July 31, 2024
    Pepinemab is believed to block astrocyte reactivity, a key pathology driving Alzheimer’s progression 
    From Vaccinex, Inc.
    Via GlobeNewswire
    Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease
    From Vaccinex, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    Why SentinelOne Shares Are Trading Lower By 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update
    From Vaccinex, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    Vaccinex Reports 2023 Financial Results and Provides Corporate Update
    From Vaccinex, Inc.
    Via GlobeNewswire
    Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
    From Vaccinex, Inc.
    Via GlobeNewswire
    Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology
    From Vaccinex, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.